Last updated: April 22, 2025
Sponsor: Massachusetts General Hospital
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
N/ATreatment
BMT-VR
Clinical Study ID
NCT05629676
22-486
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adult patients (age > 18 years) with hematologic malignancy admitted for autologousor allogeneic BMT
Ability to comprehend, read, and respond to questions in English as BMT-VR is onlyavailable in English
Exclusion
Exclusion Criteria:
Patients undergoing BMT for benign hematologic conditions
Patients undergoing outpatient BMT
Patients with acute or unstable psychiatric or cognitive conditions which thetreating clinicians believes prohibits informed consent or compliance with studyprocedures
Study Design
Total Participants: 80
Treatment Group(s): 1
Primary Treatment: BMT-VR
Phase:
Study Start date:
December 20, 2022
Estimated Completion Date:
December 30, 2026
Study Description
Connect with a study center
Massachusetts General Hospital Cancer Center
Boston, Massachusetts 02114
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.